Association of aldosterone concentration and mineralocorticoid receptor genotype with potassium response to spironolactone in patients with heart failure

Pharmacotherapy

Volumn 30, Issue 1, 2010, Pages 1-9

  Cavallari, Larisa H ^a   Groo, Vicki L ^a   Viana, Marlos A G ^a,b   Dai, Yang ^c   Patel, Shitalben R ^a   Stamos, Thomas D ^b  

^a UNIVERSITY OF ILLINOIS AT CHICAGO   (United States)

^b UNIVERSITY OF ILLINOIS   (United States)

^c University of Illinois at Chicago   (United States)

Author keywords

Aldosterone; Heart failure; Mineralocorticoid; Potassium; Spironolactone

Indexed keywords

ALDOSTERONE; ALDOSTERONE ANTAGONIST; ANGIOTENSINOGEN; MINERALOCORTICOID RECEPTOR; NUCLEAR RECEPTOR 3C2; POTASSIUM; SPIRONOLACTONE; UNCLASSIFIED DRUG;

ADULT; ARTICLE; BLOOD CHEMISTRY; CLINICAL ASSESSMENT; COHORT ANALYSIS; CONFIDENCE INTERVAL; DRUG DOSE TITRATION; FEMALE; GENE FREQUENCY; GENETIC ASSOCIATION; GENOTYPE; HEART FAILURE; HETEROZYGOTE; HUMAN; MAJOR CLINICAL STUDY; MALE; POTASSIUM BLOOD LEVEL; PREDICTION; PROSPECTIVE STUDY; REGRESSION ANALYSIS; TREATMENT RESPONSE;

ADULT; AFRICAN AMERICANS; AGED; ALDOSTERONE; ALDOSTERONE ANTAGONISTS; ANGIOTENSINOGEN; COHORT STUDIES; DIURETICS; EUROPEAN CONTINENTAL ANCESTRY GROUP; FEMALE; GENOTYPE; HEART FAILURE; HUMANS; HYPERKALEMIA; MALE; MIDDLE AGED; POTASSIUM; RECEPTORS, MINERALOCORTICOID; SPIRONOLACTONE; STATISTICS AS TOPIC;

EID: 75149149183     PISSN: 02770008     EISSN: None     Source Type: Journal    
DOI: 10.1592/phco.30.1.1     Document Type: Article

References (32)

1. Chacko M, Fordtran JS, Emmett M. Effect of mineralocorticoid activity on transtubular potassium gradient, urinary [K]/[Na] ratio, and fractional excretion of potassium. Am J Kidney Dis 1998;32:47-51.
2. Brilla CG, Zhou G, Matsubara L, Weber KT. Collagen metabolism in cultured adult rat cardiac fibroblasts: response to angiotensin II and aldosterone. J Mol Cell Cardiol 1994;26:809-20.
3. Pitt B, Zannad F, Remme WJ, et al, for the Randomized Aldactone Evaluation Study Investigators. The effect of spironolactone on morbidity and mortality in patients with severe heart failure. N Engl J Med 1999;341:709-17.
4. Hunt SA, Abraham WT, Chin MH, et al. 2009 focused update incorporated into the ACC/AHA 2005 guidelines for the diagnosis and management of heart failure in adults: a report of the American College of Cardiology Foundation/American Heart Association task force on practice guidelines developed in collaboration with the International Society for Heart and Lung Transplantation. J Am Coll Cardiol 2009;53:e1-90.
5. RALES Investigators. Effectiveness of spironolactone added to an angiotensin-converting enzyme inhibitor and a loop diuretic for severe chronic congestive heart failure: the randomized aldactone evaluation study (RALES). Am J Cardiol 1996;78:902-7.
6. Svensson M, Gustafsson F, Galatius S, Hildebrandt PR, Atar D. How prevalent is hyperkalemia and renal dysfunction during treatment with spironolactone in patients with congestive heart failure? J Card Fail 2004;10:297-303.
7. Ramadan FH, Masoodi N, El-Solh AA. Clinical factors associated with hyperkalemia in patients with congestive heart failure. J Clin Pharm Ther 2005;30:233-9.
8. Desai AS, Swedberg K, McMurray JJ, et al. Incidence and predictors of hyperkalemia in patients with heart failure: an analysis of the CHARM program. J Am Coll Cardiol 2007;50:1959-66.
9. Cavallari LH, Groo VL, Momary KM, Fontana D, Viana MA, Vaitkus P. Racial differences in potassium response to spironolactone in heart failure. Congest Heart Fail 2006;12:200-5.
10. Cavallari LH, Fashingbauer LA, Beitelshees AL, et al. Racial differences in patients' potassium concentrations during spironolactone therapy for heart failure. Pharmacotherapy 2004;24:750-6.
11. Arai K, Nakagomi Y, Iketani M, et al. Functional polymorphisms in the mineralocorticoid receptor and amiloridesensitive sodium channel genes in a patient with sporadic pseudohypoaldosteronism. Hum Genet 2003;112:91-7.
12. Database of Single Nucleotide Polymorphisms (dbSNP). Bethesda, MD: National Center for Biotechnology Information, National Library of Medicine. dbSNP accession: ss22887607, (dbSNP Build ID: 130). Available from http://www.ncbi.nlm.nih.gov/SNP/. Accessed July 29, 2009.
13. Database of Single Nucleotide Polymorphisms (dbSNP). Bethesda, MD: National Center for Biotechnology Information, National Library of Medicine. dbSNP accession: ss23731817, ss44492050, (dbSNP Build ID: 130). Available from http://www.ncbi.nlm.nih.gov/SNP/. Accessed July 29, 2009.
14. Inoue I, Nakajima T, Williams CS, et al. A nucleotide substitution in the promoter of human angiotensinogen is associated with essential hypertension and affects basal transcription in vitro. J Clin Invest 1997;99:1786-97.
15. Fardella C, Zamorano P, Mosso L, et al. A(-6)G variant of angiotensinogen gene and aldosterone levels in hypertensives. Hypertension 1999;34:779-81.
16. Schunkert H, Hense HW, Gimenez-Roqueplo AP, et al. The angiotensinogen T235 variant and the use of antihypertensive drugs in a population-based cohort. Hypertension 1997;29:628-33.
17. Hingorani AD, Jia H, Stevens PA, Hopper R, Dickerson JE, Brown MJ. Renin-angiotensin system gene polymorphisms influence blood pressure and the response to angiotensin-converting enzyme inhibition. J Hypertens 1995;13:1602-9.
18. Kurland L, Melhus H, Karlsson J, et al. Polymorphisms in the angiotensinogen and angiotensin II type 1 receptor gene are related to change in left ventricular mass during antihypertensive treatment: results from the Swedish irbesartan left ventricular hypertrophy investigation versus atenolol (SILVHIA) trial. J Hypertens 2002;20:657-63.
19. Database of Single Nucleotide Polymorphisms (dbSNP). Bethesda, MD: National Center for Biotechnology Information, National Library of Medicine. dbSNP accession: ss86211282, (dbSNP Build ID: 130). Available from http://www.ncbi.nlm.nih.gov/SNP/. Accessed July 29, 2009.
20. Database of Single Nucleotide Polymorphisms (dbSNP). Bethesda, MD: National Center for Biotechnology Information, National Library of Medicine. dbSNP accession: ss86211304, (dbSNP Build ID: 130). Available from http://www.ncbi.nlm.nih.gov/SNP/. Accessed July 29, 2009.
21. Hurwitz S, Cohen RJ, Williams GH. Diurnal variation of aldosterone and plasma renin activity: timing relation to melatonin and cortisol and consistency after prolonged bed rest. J Appl Physiol 2004;96:1406-14.
22. Lamarre-Cliche M, de Champlain J, Lacourciere Y, Poirier L, Karas M, Larochelle P. Effects of circadian rhythms, posture, and medication on renin-aldosterone interrelations in essential hypertensives. Am J Hypertens 2005;18:56-64.
23. Cockcroft DW, Gault MH. Prediction of creatinine clearance from serum creatinine. Nephron 1976;16:31-41.
24. Dempster A, Laird N, Rubin D. Maximum likelihood from incomplete data via the EM algorithm. J R Stat Soc Series B 1997;39:1-38.
25. Juurlink DN, Mamdani MM, Lee DS, et al. Rates of hyperkalemia after publication of the randomized aldactone evaluation study. N Engl J Med 2004;351:543-51.
26. Bozkurt B, Agoston I, Knowlton AA. Complications of inappropriate use of spironolactone in heart failure: when an old medicine spirals out of new guidelines. J Am Coll Cardiol 2003;41:211-14.
27. Kozak M. Point mutations close to the AUG initiator codon affect the efficiency of translation of rat preproinsulin in vivo. Nature 1984;308:241-6.
28. Morle F, Lopez B, Henni T, Godet J. α-Thalassaemia associated with the deletion of two nucleotides at position -2 and -3 preceding the AUG codon. Embo J 1985;4:1245-50.
29. Kanaji T, Okamura T, Osaki K, et al. A common genetic polymorphism (46 C to T substitution) in the 5′-untranslated region of the coagulation factor XII gene is associated with low translation efficiency and decrease in plasma factor XII level. Blood 1998;91:2010-14.
30. Poch E, Gonzalez D, Giner V, Bragulat E, Coca A, de La Sierra A. Molecular basis of salt sensitivity in human hypertension: evaluation of renin-angiotensin-aldosterone system gene polymorphisms. Hypertension 2001;38:1204-9.
31. Tobin MD, Tomaszewski M, Braund PS, et al. Common variants in genes underlying monogenic hypertension and hypotension and blood pressure in the general population. Hypertension 2008;51:1658-64.
32. Lombes M, Alfaidy N, Eugene E, Lessana A, Farman N, Bonvalet JP. Prerequisite for cardiac aldosterone action: mineralocorticoid receptor and 11 β-hydroxysteroid dehydrogenase in the human heart. Circulation 1995;92:175-82.